EFPIA vice president urges Japan to enhance its competitiveness

15 April 2007

"Japan is now facing the same situation as Europe came across several years ago in losing its international competitiveness in the pharmaceutical sector," Jean-Francois Dehecq, vice president of the European Federation of Pharmaceutical Industries and Associations and chairman of France's drug giant Sanofi-Aventis, said at a press conference in Tokyo.

Mr Dehecq spoke of the reasons for the loss of its international competitiveness by the Japanese pharmaceutical industry, how to improve both the environment for clinical trials and the drug review and approval system in Japan.

Stakeholder communication in Europe "has improved"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight